Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET

Company Participants

Juan Sanchez - VP, Corporate Communications & IR
Sharon Mates - Founder, Chairman and CEO
Mark Neumann - EVP and CCO
Sanjeev Narula - CFO
Suresh Durgam - EVP and CMO

Conference Call Participants

Andrew Tsai - Jefferies
Jessica Fye - JPMorgan
Charles Duncan - Cantor
Jason Gerberry - Bank of America Securities
Jeff Hung - Morgan Stanley
Michael DiFiore - Evercore
David Amsellem - Piper Sandler
Joel Beatty - Baird
Corinne Johnson - Goldman Sachs

Operator

Good day and thank you for standing by. Welcome to Intra-Cellular Therapies 3Q 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would like now to hand the call over to Juan Sanchez, Head of Investor Relations. Please go ahead.

Juan Sanchez

Good morning and thank you all for joining us on our third quarter 2024 earnings call. Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer; Mark Neumann, Chief Commercial Officer; Dr. Suresh Durgam, Chief Medical Officer; and Sanjeev Narula, Chief Financial Officer.

A slide deck to complement today's call is available under the Investors Events section of our corporate website.

During today's call, we will be making certain forward-looking statements. These forward-looking statements are based on current information, assumptions, and expectations. Those statements are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements.

These and other risks are described in our periodic filings made with the Securities and Exchange Commission, including our quarterly and annual reports. You're cautioned not to place undue reliance on these forward-looking statements. These statements are made only as of the date of this conference call and the company disclaims any obligations to update such statements.

I will now turn the call over to Sharon.

Sharon Mates

Thanks Juan. Good morning and welcome to our third quarter earnings call. We are pleased to share our Q3 results and to describe the exciting progress we have made across the company.

CAPLYTA's growth trajectory continues to reflect a compelling product profile and our successful commercial execution with net sales of $175.2 million in the third quarter, representing a 39% increase over the third quarter of 2023. Based on this continued strong performance, we are raising our 2024 full year net sales guidance range to $665 million to $685 million.